Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00420264 · ClinicalTrials.gov registry record · NA

ThermaChoice III Under Local Sedation in the Office Setting

A NA study of Heavy Uterine Bleeding, sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT00420264 is a NA study of Heavy Uterine Bleeding that has completed, run by Female Pelvic Medicine & Urogynecology Institute of Michigan. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00420264, a NA study of Heavy Uterine Bleeding, has completed, sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

Investigational study to determine if an endometrial ablation for heavy uterine bleeding, can be tolerated in the office setting without the use of intravenous medication.

Conditions Studied

Interventions

  • DEVICE Uterine Ablation

Study Locations (1)

Michigan

  • Grand Valley Gynecologists, PC - Grand Rapids

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2005-11
Est. Completion 2009-05
Phase NA

What the Registry Record Tells You About NCT00420264

The ClinicalTrials.gov registry entry for NCT00420264 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Female Pelvic Medicine & Urogynecology Institute of Michigan, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heavy Uterine Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Uterine Ablation is the first listed.

NCT00420264 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT00420264 about?

NCT00420264 is a clinical study titled "ThermaChoice III Under Local Sedation in the Office Setting". Investigational study to determine if an endometrial ablation for heavy uterine bleeding, can be tolerated in the office setting without the use of intravenous medication.

What is the current status of trial NCT00420264?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2005-11. Estimated completion is 2009-05.

What conditions does trial NCT00420264 study?

This clinical trial studies the following conditions: Heavy Uterine Bleeding.

What interventions are being tested in trial NCT00420264?

The interventions under investigation include: Uterine Ablation (DEVICE).

Who is sponsoring clinical trial NCT00420264?

This trial is sponsored by Female Pelvic Medicine & Urogynecology Institute of Michigan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00420264 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heavy Uterine Bleeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.